Researchers reported a new approach to connect biology with outcomes in lung cancer immunotherapy by using blood-based protein signatures. The work focuses on identifying who benefits from checkpoint inhibitor regimens, aiming to address the recurring clinical problem that some patients achieve durable responses while others progress without meaningful benefit. The study also reflects a broader move toward measurable peripheral biomarkers rather than relying only on baseline tumor features.